News

Novo Nordisk AS (NVO) reports significant sales and profit growth, driven by obesity care expansion and strategic collaborations, despite challenges in the US market.
Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...
The latest announcement is out from Septerna, Inc. ( (SEPN) ).
Recently, Novo Nordisk signed a $2.2 billion deal with Septerna for developing and commercializing oral small-molecule medicines for treating obesity, T2D and other cardiometabolic diseases.
Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...
Septerna is also eligible to receive tiered royalties on global net sales of marketed products. Novo Nordisk will cover all R&D expenses for partnered programs under the collaboration.
Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company’s innovative ...
HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.
In a deal that could top out at about $2.2 billion, Septerna Inc. is getting $200 million up front from Novo Nordisk A/S in a collaboration to develop oral treatments for obesity, type 2 diabetes and ...
Under the agreement, Novo Nordisk will pay more than $200 million up front, with Septerna eligible to receive up to $2.2 billion based on development.